Preview Mode Links will not work in preview mode

Journal of Clinical Oncology recognizes that readers do not always have time to review an article in depth, and yet they still wish to understand how the results will influence their clinical practice or research. To address this need, we offer podcasts that will enhance the readership experience by presenting the key results of high-profile publications in a convenient audio format. Our podcasts are designed to place selected articles into a clinically useful perspective that is easy to listen to in the office or while on the road.

Life is busy, and it’s hard to get it all done during business hours! Journal of Clinical Oncology recognizes that you do not always have time to review an article in depth, and yet you wish to understand how the results will influence your clinical practice or research. JCO After Hours is a podcast intended to enhance the readership experience by presenting key results of high-profile publications in a convenient audio format, placing selected articles into a clinically useful perspective that you can listen to in the office or on the road.

Sep 29, 2011

Rapid, dramatic shifts are ongoing in the population-level epidemiology of oropharynx cancer in the United States.


Sep 29, 2011

EGFR mutation is a predictive biomarker for maintenance erlotinib but its clinical application is limited. This podcast will explain why.


Sep 26, 2011

This podcast summarizes the incidence and long-term outcome of osteonecrosis in a large prospective study of children treated for acute lymphhoblastic leukemia with the dexamethasone-based Dutch Childhood Oncology Group-ALL 9 Protocol.


Sep 15, 2011

This podcast evaluates the context and reviews results of a randomized phase III trial comparing R-CHOP given at conventional 21 day intervals with R-CHOP given at 14 day intervals in patients with newly diagnosed follicular lymphoma.


Sep 12, 2011

This podcast reviews the randomized double-blind placebo-controlled trial reported by Boekhout et al. that evaluates venlafaxine and clonidine for the treatment of hot flashes in women with breast cancer.